Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by Laine1on May 21, 2010 2:27pm
546 Views
Post# 17122860

RE: NIHSS decrease and sp next week?

RE: NIHSS decrease and sp next week?Highly unlikely there will be a decrease in the NIHSS.
As another poster stated, the only variable here is the Epo. We already have the results of 14 patients who have undergone treatment and the score was 8.8. It was statistically consistent, if not significant, between the two combined trials.
If there was to be a statistical error with the small number of patients in the meta analysis it would most likely be to the downside - meaning it would have been lower.  The greater the number of patients enrolled, the less impact potential non-responders will have.
Just for argument sake - let's say that 50% of the Phase 11b patients are non responders and the rest respond consistent with the meta analysis, we would still arrive at an NIHSS decrease of somewhere around 5 for all cohorts combined. That is with HALF showing no response from treatment. The only way that any of the 14 patients already treated could have shown no response is if some of the other scored at 9, 10 or higher.  The numbers are right there.
Bullboard Posts